Claim your listing
Home Supplements Peptides
Tier 2 · Mechanistic

Therapeutic Peptides:
Mechanism-First,
Marketing-Last

The peptide category combines some of the strongest mechanistic rationale in longevity science with some of the weakest human clinical evidence. One compound here has full Phase III trial data and MHRA-approved licensed-medicine status. Several others are research chemicals with no human use approval at all. Knowing which is which matters.

Tier 2 reflects the category average. Individual peptides range from Tier 1 (semaglutide — licensed medicine with extensive RCT data) to Tier 3 (BPC-157, Epithalon — preclinical or very limited human data). See individual compound cards below.

Category: Peptides

Compounds covered
6 longevity-relevant peptides
Evidence range
Phase III RCTs (semaglutide) to case reports (BPC-157)
UK licensed
1 of 6 (semaglutide / Wegovy / Ozempic)
Research chemicals
3 of 6 — no MHRA human use approval

What are peptides

Short chains. Precise signals. Inconsistent evidence.

Peptides are short chains of amino acids — typically 2 to 50 residues — that act as biological signalling molecules. They are structurally simpler than proteins but functionally specific: each peptide binds to defined receptors or interacts with particular cellular pathways, triggering downstream effects that can be highly targeted. This is the source of the category's genuine therapeutic promise. It is also the source of its marketing vulnerability: mechanistic plausibility is compelling, and it is easy to mistake a well-characterised mechanism for a well-evidenced clinical outcome.

Longevity-relevant peptides generally fall into three functional groups. Growth hormone secretagogues (CJC-1295, Ipamorelin) stimulate the pituitary to release more GH, elevating IGF-1 — an axis associated with tissue repair and body composition changes. Tissue repair and regeneration signals (BPC-157, TB-500, Thymosin Beta-4) promote angiogenesis, reduce inflammation, and accelerate healing in animal models. Metabolic modulators (semaglutide and related GLP-1 agonists) alter appetite regulation, insulin sensitivity, and — increasingly — appear to have cardiovascular and metabolic benefits beyond weight management.

The UK regulatory position varies substantially across the category. Some peptides are fully licensed medicines with clear prescription routes (semaglutide). Some fall into a grey area where they may be classified as medicinal products if sold for human use, requiring a prescription even if unlicensed (CJC-1295, PT-141). Others are classified as research chemicals — meaning they have no approved human use indication and their supply chain quality is unregulated (BPC-157, TB-500, Epithalon).

Compound profiles

Six peptides — mechanism, evidence, and UK status

Each card below summarises one compound. The coloured top border and tier chip reflect the current state of human clinical evidence — not mechanistic promise, not preclinical data, not anecdotal reports. Evidence tier colours: green = Tier 1 (Human RCTs), amber = Tier 2 (Mechanistic / early human), red-orange = Tier 3 (Emerging / preclinical-dominant).

BPC-157

Body Protection Compound-157
T3 · Emerging

Mechanism

Promotes angiogenesis, tendon and ligament repair, and gut mucosal healing. Acts through modulation of growth hormone receptor expression and nitric oxide pathways. Strong anti-inflammatory profile in animal models.

Human evidence

Case reports and one small Croatian RCT in peptic ulcer disease (1993). Extensive preclinical data in rats — the volume of rat studies is the source of most of the claims circulating online. No Phase II or Phase III RCTs exist in humans for the indications popular in biohacking communities.

UK: Research chemical · No MHRA human use approval

Popular in sports recovery and biohacker communities. The marketing claims (tendon repair, gut healing) are not matched by human clinical evidence.

TB-500

Thymosin Beta-4 synthetic fragment
T3 · Emerging

Mechanism

Binds to actin to promote cell migration and differentiation. Anti-inflammatory, supports angiogenesis and wound healing. Acts on cardiac and skeletal muscle repair pathways in animal models.

Human evidence

Minimal direct human data. One Phase II trial exists in epidermolysis bullosa (a rare skin blistering condition). The longevity and recovery applications are based on preclinical studies and extrapolation from veterinary use — TB-500 is widely used in racehorse recovery.

UK: Research chemical · No MHRA human use approval

Most available data is from equine veterinary studies. Human evidence is not yet sufficient to support the recovery and longevity claims.

Semaglutide

GLP-1 receptor agonist (Ozempic / Wegovy)
T1 · RCTs

Mechanism

GLP-1 receptor agonist — an incretin mimetic that slows gastric emptying, suppresses appetite centrally, and stimulates glucose-dependent insulin secretion. Growing evidence for anti-inflammatory effects and possible cardiovascular and neuroprotective mechanisms beyond metabolic action.

Human evidence

Extensive. SUSTAIN trial programme (T2D); STEP trial programme (obesity); cardiovascular outcomes data from LEADER and SUSTAIN-6. FDA-approved for T2D (Ozempic) and obesity (Wegovy). SELECT trial demonstrated 20% reduction in major adverse cardiovascular events in people with obesity without diabetes.

UK: Licensed medicine · Ozempic & Wegovy · Prescription only

Covered in depth in The Compound: GLP-1 2026 — Branded vs Compounded →

CJC-1295 / Ipamorelin

GHRH analogue + selective GHRP stack
T2 · Mechanistic

Mechanism

CJC-1295 is a modified GHRH analogue that stimulates the pituitary to release growth hormone over an extended window (DAC modification extends half-life to ~8 days). Ipamorelin is a selective GHRP — a ghrelin mimetic that augments GH release without significant cortisol or prolactin elevations. Used together, the stack produces sustained IGF-1 elevation.

Human evidence

CJC-1295 has published Phase I/II pharmacokinetic and pharmacodynamic studies confirming GH and IGF-1 elevation. Clinical outcome data (body composition, muscle mass, recovery) is limited and primarily observational. No large RCTs for longevity or anti-ageing indications.

UK: Prescription-only if classified as medicinal product

Available through specialist anti-ageing clinics on a private prescription basis. Quality and legality of online-sourced product is unverified.

Epithalon

Epitalon · tetrapeptide Ala-Glu-Asp-Gly
T3 · Emerging

Mechanism

Synthetic tetrapeptide claimed to activate telomerase, the enzyme that adds telomere repeats to chromosome ends. Also described as influencing melatonin production and circadian regulation through the pineal gland. Research originates almost entirely from Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology.

Human evidence

Limited — primarily Russian-language observational studies in older adults and cancer patients. Melatonin normalisation has been reported. No Western peer-reviewed Phase II or Phase III RCTs. The telomerase activation claim has not been replicated in well-controlled human studies.

UK: Research chemical · No MHRA approval

Unverified supply chain. Claims of telomere extension in humans are not supported by replicated controlled trial data.

PT-141

Bremelanotide · Vyleesi (FDA-approved)
T2 · Mechanistic

Mechanism

Melanocortin receptor agonist acting at MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors (sildenafil), its mechanism is central — it activates sexual arousal pathways in the brain rather than improving peripheral blood flow. This distinction matters: it works in people without vascular pathology.

Human evidence

FDA-approved (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Phase III trial data exists for that indication. The longevity and vitality use-cases are off-label extrapolations. Nausea and transient blood pressure elevation are the most common adverse effects in trials.

UK: Not MHRA-licensed · Prescription-only if classified as medicinal

Vyleesi is not licensed in the UK. Available through private clinics as an unlicensed import. Phase III evidence exists for the HSDD indication only.

Several peptides listed here are not approved for human use in the UK. This page is educational. Do not self-administer peptides sourced from unregulated suppliers — product purity, dose accuracy, and sterility cannot be verified outside a regulated pharmaceutical supply chain. Research chemicals sold for "laboratory use only" carry no quality guarantees when used by humans.

UK Regulatory Overview

Three categories. Three different risk profiles.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) classifies products according to whether they meet the definition of a medicinal product — broadly, whether they are presented as treating, preventing, or curing a disease, or whether they function pharmacologically in a way that affects a physiological function. This classification is not about molecular structure. A compound can cross from "research chemical" to "unlicensed medicine" depending on how it is sold and labelled.

Category 1 — Licensed medicines

  • Semaglutide (Ozempic, Wegovy)
  • Full MHRA approval; established prescription route through NHS or private GP
  • Quality, dose, and safety profile are regulated

Category 2 — Unlicensed, prescription-only

  • CJC-1295, Ipamorelin, PT-141
  • May be prescribed by a UK doctor as an unlicensed medicine under the "specials" framework
  • Available through private anti-ageing clinics — quality depends on source

Category 3 — Research chemicals

  • BPC-157, TB-500, Epithalon
  • No MHRA-approved human use pathway
  • Sold legally for laboratory research only — human use is off-label with no regulatory oversight of supply chain quality

Limitations

What the peptide evidence base does not show

  • Longevity extension in humans. No peptide covered here has a human trial measuring mortality as an outcome. Semaglutide has the strongest cardiovascular outcomes data, but this is not equivalent to lifespan extension evidence.
  • Replicated clinical efficacy for BPC-157, TB-500, or Epithalon in well-controlled human RCTs. The animal model data is extensive; the human clinical data is not.
  • Verified safety of research chemical peptides at the doses commonly discussed in self-administration communities. Purity, dose accuracy, and contamination risk from unregulated sources are not quantified.
  • Direct comparison between peptide stacks and other interventions — exercise, nutrition, sleep, and other lifestyle variables that share the same mechanistic pathways with better human evidence.
  • Long-term safety data for growth hormone secretagogue use (CJC-1295/Ipamorelin). Chronic IGF-1 elevation has complex relationships with cancer risk and other longevity-relevant pathways that are not resolved by short-term pharmacokinetic studies.

This is educational information only. Several compounds on this page are not licensed for human use in the UK. Nothing here constitutes medical advice. Always consult a qualified healthcare professional and verify UK regulatory status with the MHRA before using any peptide product. ProvenLongevity has no commercial relationship with any supplier or clinic mentioned.